Narrowed losses at GW Pharmaceuticals
Friday 20 June 2008
GW Pharmaceuticals, the UK drug maker that is licensed to use cannabis in its treatments, posted first half numbers yesterday showing narrowed losses.
The group said that half-year losses were £4.2m, down from £7.6m last year. GW's cash position stands at £18.5m, which will cover research for its Sativex treatment, used to treat a range of conditions from multiple sclerosis, diabetes and pain among cancer sufferers, says chief executive Justin Gover.
A third phase trial for multiple sclerosis usage will be completed in the fourth quarter and is, "as close to a certainty as you can get," says Ibraheem Mahmood, an analyst at Investec.
Geoffrey Macnab reviews American Hustle, also starring Christian Bale and Bradley Cooper
Dennis Rodman will coach the North Korea basketball team
Jennifer Lawrence: 'It should be illegal to call someone fat on TV'
Ian Watkins: Police probed over earlier allegations as paedophile Lostprophets singer sentenced to 35 years for child sex offences
Iain Duncan Smith leaves Commons food banks debate early
DNA from a 50,000 year old toe shows Neanderthals were highly inbred
Devyani Khobragade: India-US row escalates over arrest of diplomat in New York
- 1 America's 'virgin births'? One in 200 mothers 'became pregnant without having sex'
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 3 Christmas comes early: Justin Bieber is 'retiring from music'
- 4 Iain Duncan Smith leaves Commons food banks debate early
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
iJobs Money & Business
£500 - £550 per day: Cornwallis Elt : Business Analyst Target Operating Mod...
£500 - £680 per day: Harrington Starr: Murex Business Analyst - 1000 CHF per d...
£60000 - £75000 per annum + Bonus and Benefits: Harrington Starr: A leading au...
£25000 - £32000 per annum: Harrington Starr: Junior Business Analyst - Banking...